Literature DB >> 14688119

Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design.

Johan Vekemans1, Martin O C Ota, Jackson Sillah, Katherine Fielding, Mark R Alderson, Yasir A W Skeiky, Wilfried Dalemans, Keith P W J McAdam, Christian Lienhardt, Arnaud Marchant.   

Abstract

Recombinant immunodominant mycobacterial antigens are needed for the development of new vaccines and immunodiagnostic tools for use against tuberculosis. Ubiquitous exposure to mycobacteria in tropical countries could influence vaccine-induced immunity and the specificity of tuberculosis immunodiagnosis. For this study conducted in The Gambia, cellular immune responses to recombinant mycobacterial antigens were characterized in Mycobacterium bovis BCG-vaccinated and nonvaccinated infants, adult community controls, household contacts, health care workers, and tuberculosis patients. Neonatal BCG vaccination induced gamma interferon (IFN-gamma) responses to Mtb8.4, Mtb32-C, Mtb39A, Mtb9.9A, and Mtb32-N, but not CFP-10 (Mtb11) and alpha-crystallin (Mtb16). Exposure to Mycobacterium tuberculosis in household contacts and health care workers was associated with high responses to CFP-10 and alpha-crystallin. Generally, low IFN-gamma responses were found in tuberculosis patients. These results suggest that Mtb8.4, Mtb32-C, Mtb39A, Mtb9.9A, and Mtb32-N may be used in a subunit vaccine to boost BCG-induced immunity. While CFP-10 and alpha-crystallin are promising candidates for the immunodiagnosis of M. tuberculosis infection or for vaccine use, disease-associated immunosuppression may prevent IFN-gamma immunodiagnosis of more advanced tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688119      PMCID: PMC343957          DOI: 10.1128/IAI.72.1.381-388.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design.

Authors:  C Lienhardt; S Bennett; G Del Prete; O Bah-Sow; M Newport; P Gustafson; K Manneh; V Gomes; A Hill; K McAdam
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

2.  Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes.

Authors:  J Vekemans; A Amedei; M O Ota; M M D'Elios; T Goetghebuer; J Ismaili; M J Newport; G Del Prete; M Goldman; K P McAdam; A Marchant
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

3.  Uncommon presentations of tuberculosis: the potential value of a novel diagnostic assay based on the Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10.

Authors:  S M Arend; T H Ottenhoff; P Andersen; J T van Dissel
Journal:  Int J Tuberc Lung Dis       Date:  2001-07       Impact factor: 2.373

4.  Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia.

Authors:  J Vekemans; C Lienhardt; J S Sillah; J G Wheeler; G P Lahai; M T Doherty; T Corrah; P Andersen; K P McAdam; A Marchant
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis.

Authors:  A Lalvani; R Brookes; R J Wilkinson; A S Malin; A A Pathan; P Andersen; H Dockrell; G Pasvol; A V Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

6.  Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.

Authors:  R N Coler; A Campos-Neto; P Ovendale; F H Day; S P Fling; L Zhu; N Serbina; J L Flynn; S G Reed; M R Alderson
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

7.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.

Authors:  Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

8.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Authors:  Alexander S Pym; Priscille Brodin; Laleh Majlessi; Roland Brosch; Caroline Demangel; Ann Williams; Karen E Griffiths; Gilles Marchal; Claude Leclerc; Stewart T Cole
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

10.  Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo.

Authors:  Christian Lienhardt; Annalisa Azzurri; Amedeo Amedei; Katherine Fielding; Jackson Sillah; Oumou Y Sow; Boubacar Bah; Marisa Benagiano; Alimou Diallo; Roberto Manetti; Kebba Manneh; Per Gustafson; Steve Bennett; Mario M D'Elios; Keith McAdam; Gianfranco Del Prete
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

View more
  19 in total

1.  Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.

Authors:  K F Siddiqui; M Amir; N Khan; G Rama Krishna; J A Sheikh; K Rajagopal; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

2.  Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice.

Authors:  Virginie Roupie; Marta Romano; Lei Zhang; Hannelie Korf; May Young Lin; Kees L M C Franken; Tom H M Ottenhoff; Michèl R Klein; Kris Huygen
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

3.  T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination.

Authors:  Annemieke Geluk; May Young Lin; Krista E van Meijgaarden; Eliane M S Leyten; Kees L M C Franken; Tom H M Ottenhoff; Michèl R Klein
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

4.  DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy.

Authors:  Andrea M Hebert; Sarah Talarico; Dong Yang; Riza Durmaz; Carl F Marrs; Lixin Zhang; Betsy Foxman; Zhenhua Yang
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

5.  In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis.

Authors:  R Al-Attiyah; A S Mustafa; A T Abal; A S M El-Shamy; W Dalemans; Y A W Skeiky
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

6.  Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia.

Authors:  David J C Miles; Marianne van der Sande; Sarah Crozier; Olubukola Ojuola; Melba S Palmero; Mariama Sanneh; Ebrima S Touray; Sarah Rowland-Jones; Hilton Whittle; Martin Ota; Arnaud Marchant
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

7.  Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.

Authors:  May Young Lin; Annemieke Geluk; Steven G Smith; Amanda L Stewart; Annemieke H Friggen; Kees L M C Franken; Marleen J C Verduyn; Krista E van Meijgaarden; Martin I Voskuil; Hazel M Dockrell; Kris Huygen; Tom H M Ottenhoff; Michèl R Klein
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

8.  Murine neonatal recent thymic emigrants are phenotypically and functionally distinct from adult recent thymic emigrants.

Authors:  Shannon J Opiela; Tulay Koru-Sengul; Becky Adkins
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

9.  Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients.

Authors:  Anbarasu Deenadayalan; Darragh Heaslip; Adhilakshmi Aavudaiyappan Rajendiran; Banurekha Vaithilingam Velayudham; Sheela Frederick; Hong-Liang Yang; Karen Dobos; John T Belisle; Alamelu Raja
Journal:  Mol Cell Proteomics       Date:  2009-12-22       Impact factor: 5.911

10.  Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.

Authors:  Priyanka Chauhan; Ruchi Jain; Bappaditya Dey; Anil K Tyagi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.